Array Biopharma, Inc. (ARRY) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $3.80 +12.09%
EPS Growth %: -70.0%
Financial Fact:
Research and development for proprietary programs: 46.56M
Today's EPS Names:
LTBR, AES, SYRS, More
EPS Growth %: -70.0%
Financial Fact:
Research and development for proprietary programs: 46.56M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
On Monday, Array Biopharma, Inc. (NASDAQ: ARRY) reported Q1 EPS of ($0.13), $0.02 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $15.8 million versus the consensus estimate of $16.7 million.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- Neurocrine Biosciences (NBIX) Tops Q3 EPS by 138c
- Janus Living, Inc. (JAN) Reports Q3 Loss of $0.02 ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
